Interés Humano

EE. UU. aprueba plenamente uso del antiviral remdesivir en pacientes de covid-19

FDA dio total aval a tratamiento específico contra el coronavirus luego de una autorización condicional acordada en mayo

(FILES) In this file photo one vial of the drug Remdesivir is viewed during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020, amidst the new coronavirus COVID-19 pandemic. - Gilead Science's remdesivir, one of the most highly anticipated drugs being tested against the new coronavirus, showed positive results in a large-scale US government trial, the company said on April 29, 2020."We understand that the trial has met its primary endpoint and that NIAID (National Institute of Allergy and Infectious Diseases) will provide detailed information at an upcoming briefing," the company said. (Photo by Ulrich Perrey / POOL / AFP)
(FILES) In this file photo one vial of the drug Remdesivir is viewed during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020, amidst the new coronavirus COVID-19 pandemic. - Gilead Science's remdesivir, one of the most highly anticipated drugs being tested against the new coronavirus, showed positive results in a large-scale US government trial, the company said on April 29, 2020."We understand that the trial has met its primary endpoint and that NIAID (National Institute of Allergy and Infectious Diseases) will provide detailed information at an upcoming briefing," the company said. (Photo by Ulrich Perrey / POOL / AFP) ULRICH PERREY
Una muestra del medicamento remdesivir. Foto: AFP (ULRICH PERREY/AFP)

Washington. La agencia reguladora de medicamentos de Estados Unidos (FDA) dio este jueves una autorización plena al medicamento antiviral remdesivir para ser usado en el tratamiento de enfermos hospitalizados por covid-19, confirmando la autorización condicional acordada en mayo, informó el fabricante Gilead.

El laboratorio anunció que recibió la autorización para el medicamento y destacó que de momento se trata del único tratamiento específico contra la covid-19 aprobado tras un proceso de verificación más riguroso y definitivo.

‌
‌

‌

‌
‌

‌

‌